Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 19/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787017 | 0.87 | SLC6A9 (0.46) | SLC6A9SLC6A5 | |
| SCHEMBL787430 | 0.75 | SLC6A9 (0.55) | SLC6A9CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL786968 | 0.72 | SLC6A9 (0.70) | SLC6A9SLC6A5 | |
| SCHEMBL786894 | 0.69 | SLC6A9 (0.68) | SLC6A9 | |
| Hydrochloric Acid SCHEMBL787061 | 0.68 | SLC6A9 (0.67) | SLC6A9 | |
| SCHEMBL787544 | 0.68 | SLC6A9 (1.00) | SLC6A9SLC6A5 | |
| SCHEMBL7896447 | 0.67 | SLC6A9 (0.76) | SLC6A9SLC6A5 | |
| SCHEMBL3711335 | 0.67 | SLC6A9 (0.76) | SLC6A9SLC6A5 | |
| SCHEMBL787474 | 0.67 | SLC6A9 (0.46) | SLC6A9 | |
| SCHEMBL786955 | 0.66 | SLC6A9 (0.66) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071536-A1 | N-[(2-AZABICYCLO[2.1.1]HEX-1-YL)-ARYL-METHYL]-BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-22 | — | — | US | claimed |
| US-20120071536-A1 | N-[(2-AZABICYCLO[2.1.1]HEX-1-YL)-ARYL-METHYL]-BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071536-A1 | N-[(2-AZABICYCLO[2.1.1]HEX-1-YL)-ARYL-METHYL]-BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | HRH4, NT5C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC6A9 3512/4885SLC6A5 832/4885CYP3A4 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.